Regional gastrointestinal delivery of remogliflozin etabonate in humans

Biopharmaceutics and Drug Disposition

Volumn 34, Issue 2, 2013, Pages 79-86

  O'Connor Semmes, Robin L ^a   Sandefer, Erik P ^b   Hussey, Elizabeth K ^a   Tao, Wenli ^a   Doll, Walter J ^b   Page, Richard C ^b   Dobbins, Robert ^a  

^a GLAXOSMITHKLINE   (United States)

^b Scintipharma Inc   (United States)

Author keywords

human site absorption; InteliSite capsule; prodrug esterase; remogliflozin; SGLT2 inhibition

Indexed keywords

DRUG METABOLITE; ESTERASE; GSK 279782; REMOGLIFLOZIN ETABONATE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HYDROLYSIS; DRUG RELEASE; DRUG SOLUTION; HUMAN; INTESTINE ABSORPTION; LARGE INTESTINE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SMALL INTESTINE; SUSPENSION; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; CAPSULES; CROSS-OVER STUDIES; GASTROINTESTINAL TRACT; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; PYRAZOLES; YOUNG ADULT;

EID: 84874730934     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1824     Document Type: Article

References (10)

1. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M,. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008; 327: 268-276.
2. Dobbins R, O'Connor-Semmes R, Kapur A, et al,. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2) reduces serum glucose in type 2 diabetes mellitus (T2DM) patients. Diabetes Obes Metab 2012; 14: 15-22.
3. Kapur A, O'Connor-Semmes R, Hussey E, et al,. First human dose-escalation study with remogliflozin etabonate (RE) in healthy subjects and in subjects with type 2 diabetes mellitus (T2DM). Diabetes 2009; 58 (Suppl. 1): A136.
4. Digenis GA, Sandefer EP,. Gamma scintigraphy and neutron activation techniques in the in vivo assessment of orally administered dosage forms. Crit Rev Ther Drug Car Sys 1991; 7: 309-345.
5. Parr AF, Sandefer EP, Wissel P, et al,. Evaluation of the feasibility and use of a prototype remote drug delivery capsule (RDDC) for non-invasive regional drug absorption studies in the GI tract of man and beagle dog. Pharm Res 1999; 16: 266-271.
6. McGirr MEA, McAllister SM, Peters EE, Wickers AW, Parr AF, Basit AW,. The use of the InteliSite Companion device to deliver mucoadhesive polymers to the dog colon. Eur J Pharm Sci 2009; 36: 386-391.
7. Sigafoos JF, Bowers GD, Castellino S, et al,. Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose co-transporter-2 inhibitor: evidence from in vitro, human mass balance and ketoconazole interaction studies. Drug Metab Dispos 2012; 40 (11): 2090-2101.
8. Imai T, Ohura K,. The role of intestinal carboxylesterase in the oral absorption of prodrugs. Curr Drug Metab 2010; 11: 793-805.
9. Van Gelder J, Shafiee M, De Clercq E, et al,. Species-dependent and site-specific intestinal metabolism of ester prodrugs. Int J Pharm 2000; 205: 93-100.
10. Schwer H, Langmann T, Daig R, Becker A, Aslanides C, Schmitz G,. Molecular cloning and characterization of a novel putative carboxylesterase, present in human intestine and liver. Biochem Biophys Res Commun 1997; 233: 117-120.